Sign Up for Alerts
Sign up to receive receive industry-specific emails from our legal team.
Sign Up for Alerts
We provide tailored, industry-specific legal updates to our clients and other friends of the firm.
Areas of Interest
July 25th, 2025
Data Privacy Roundup
He provided an example of how opting in cookie tracking by clicking a bold “Allow All” button contrasted with declining tracing, which required a more involved two-step process. Mr. Goldberg pointed out that regulators saw this process as a “potential dark pattern.” “‘Symmetry of choice is the idea that it should be just as easy to accept as it is to reject,’” Goldberg said. ‘It’s an area regulators are looking very, very closely at.’” He also noted dark pattern fines, especially with the CPPA could become substantially larger. He underscored due diligence in programs, referencing recent privacy enforcement setttlements and fines. “‘All these cases involve vendor solutions that did not work,’ Goldberg said. ‘In almost all of them, the company did have privacy compliance in place; it just wasn’t working.’”
Other Quoted
Climate Diaries Cannes Lions 2026
Jeffrey A. Greenbaum is featured in the 51toCarbonZero article, Climate Diaries Cannes Lions 2026, which features eleven interviews with senior leaders from across the media and advertising industry conducted at the Cannes Lions International Festival of Creativity. Read more.
August 5 2026
‘I have been hunted down by HR reps, lawyers, and comms people:’ Developers discuss the pain and prevalence of side work clauses
Wendy Stryker was quoted in a Game Developer article discussing "side work clauses," also known as "moonlighting clauses," in video game industry employment contracts. Read more.
July 30 2026
Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads
Jeffrey A. Greenbaum was quoted in the Regulatory Affairs Professionals Society (RAPS) article, "Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads." The article discusses the FDA's proposal to eliminate the "adequate provision" requirement in direct-to-consumer (DTC) prescription drug advertising, a change that experts say could effectively result in a de facto ban on prescription drug advertisements. Read more.
July 21 2026
